Jane Street’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Jane Street’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-517	Closed	-$1.91K	–	9810
2023 Q1	$1.91K	Buy	+517	New	+$2.39K	﹤0.01%	8860
2022 Q4	–	Sell	-708	Closed	-$6K	–	10406
2022 Q3	$6K	Buy	+708	New	+$11.7K	﹤0.01%	9425
2020 Q2	–	Sell	-850	Closed	-$121K	–	7688
2020 Q1	$121K	Buy	+850	New	+$112K	﹤0.01%	4873
2014 Q3	–	Sell	-126	Closed	-$480K	–	3176
2014 Q2	$480K	Buy	126 +54	+75%	+$203K	0.01%	1448
2014 Q1	$392K	Buy	+72	New	+$379K	﹤0.01%	1773

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street's NBSE Position: Q2 2023 in Review

Jane Street sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 517 shares — an estimated $1.91K sold.

Jane Street first reported a position in NBSE in Q1 2014 and held it in 5 quarters. The position peaked at $480K in Q2 2014. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Jane Street reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jane Street sold 517 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.91K.
Jane Street first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 5 quarters.
Jane Street's NeuBase Therapeutics, Inc. Common Stock position peaked at $480K in Q2 2014.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.